All
FDA Biologics License Application Filed for Obe-Cel for Adult R/R B-ALL
November 29th 2023Following promising study results, a Biologics License Application has been filed with the FDA for obe-cel (obecabtagene autoleucel), a CAR-T cell therapy for patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL).